1Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small cell lung cancer. Lung Cancer, 2004, 43:317-322. 被引量：1
2Yang CH, Shih, JY, Chen KC, et al. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107 : 1873-1882. 被引量：1
3Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small cell lung cancer. J Clin Oncol, 2004, 22:1103-1109. 被引量：1
4Hirsch FR, Varella GM, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase Ⅲ placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol, 2006, 24:5034-5042. 被引量：1
3Bunn PA. Treatment of advanced non-small-cell lung cancer with two-drug combinations. J Clin Oncol, 2002, 20: 3565-3567. 被引量：1
4Schmidt M, Maurer-Gebhard M, Groner B, et al. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.Oncogene, 1999, 18: 1711-1721. 被引量：1
5Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor.Clin Cancer Res, 2001,7: 1459-1465. 被引量：1
6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21:2237-2246. 被引量：1
7Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial.JAMA, 2003, 290: 2149-2158. 被引量：1
8Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005,366:1527-1537. 被引量：1
9Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 2005, 23: 5900-5909. 被引量：1
10Suzuki H, Aoshiba K, Yokohori N, et al. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res, 2003, 63: 5054-5059. 被引量：1
